Given the oncogenic effects of PLCG2 on tumor cells and its role as an important contributor to the development of the tumor immunosuppressive microenvironment and the enhancement of immune escape, we hypothesized that targeted inhibition of PLCG2 expression could not only impede the malignant phenotype of tumor cells but also enhance the efficacy of anti-PD-1 therapy. Here, PLCG2 is linked to neoplasm.